Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: experience of the REMAGUS 02 phase II trial.
Valet F, de Cremoux P, Spyratos F, Servant N, Dujaric ME, Gentien D, Lehmann-Che J, Scott V, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Pierga JY, Delaloge S, Giacchetti S, Brain E, Tembo O, Marty M, Asselain B. Valet F, et al. Among authors: bertheau p. Breast. 2013 Dec;22(6):1052-9. doi: 10.1016/j.breast.2013.08.015. Epub 2013 Oct 2. Breast. 2013. PMID: 24095610 Free article. Clinical Trial.
p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors.
Varna M, Lehmann-Che J, Turpin E, Marangoni E, El-Bouchtaoui M, Jeanne M, Grigoriu C, Ratajczak P, Leboeuf C, Plassa LF, Ferreira I, Poupon MF, Janin A, de Thé H, Bertheau P. Varna M, et al. Among authors: bertheau p. Int J Cancer. 2009 Feb 15;124(4):991-7. doi: 10.1002/ijc.24049. Int J Cancer. 2009. PMID: 19048622
Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.
Lehmann-Che J, André F, Desmedt C, Mazouni C, Giacchetti S, Turpin E, Espié M, Plassa LF, Marty M, Bertheau P, Sotiriou C, Piccart M, Symmans WF, Pusztai L, de Thé H. Lehmann-Che J, et al. Among authors: bertheau p. Oncologist. 2010;15(3):246-52. doi: 10.1634/theoncologist.2009-0243. Epub 2010 Mar 12. Oncologist. 2010. PMID: 20228131 Free PMC article. Clinical Trial.
A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.
Pierga JY, Delaloge S, Espié M, Brain E, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Spielmann M, Savignoni A, Marty M. Pierga JY, et al. Among authors: bertheau p. Breast Cancer Res Treat. 2010 Jul;122(2):429-37. doi: 10.1007/s10549-010-0939-3. Epub 2010 May 18. Breast Cancer Res Treat. 2010. PMID: 20480225 Free article. Clinical Trial.
149 results